Cargando…
(18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This stud...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468130/ https://www.ncbi.nlm.nih.gov/pubmed/35608659 http://dx.doi.org/10.1007/s00415-022-11182-z |
_version_ | 1784788344607080448 |
---|---|
author | Fernandes, Mariana Mari, Luisa Chiaravalloti, Agostino Paoli, Barbara Nuccetelli, Marzia Izzi, Francesca Giambrone, Maria Pia Camedda, Riccardo Bernardini, Sergio Schillaci, Orazio Mercuri, Nicola Biagio Placidi, Fabio Liguori, Claudio |
author_facet | Fernandes, Mariana Mari, Luisa Chiaravalloti, Agostino Paoli, Barbara Nuccetelli, Marzia Izzi, Francesca Giambrone, Maria Pia Camedda, Riccardo Bernardini, Sergio Schillaci, Orazio Mercuri, Nicola Biagio Placidi, Fabio Liguori, Claudio |
author_sort | Fernandes, Mariana |
collection | PubMed |
description | INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This study aimed to measure cognitive performance, CSF biomarkers, and cerebral glucose consumption in OSA patients and to evaluate the effects of continuous positive airway pressure (CPAP) treatment on these biomarkers over a 12-month period. METHODS: Thirty-four OSA patients and 34 controls underwent (18)F-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG PET), cognitive evaluation, and CSF analysis. A subgroup of 12 OSA patients treated with beneficial CPAP and performing the 12-month follow-up was included in the longitudinal analysis, and cognitive evaluation and (18)F-FDG PET were repeated. RESULTS: Significantly reduced glucose consumption was observed in the bilateral praecuneus, posterior cingulate cortex, and frontal areas in OSA patients than controls. At baseline, OSA patients also showed lower β-amyloid(42) and higher phosphorylated-tau CSF levels than controls. Increased total tau and phosphorylated tau levels correlated with a reduction in brain glucose consumption in a cluster of different brain areas. In the longitudinal analysis, OSA patients showed an improvement in cognition and a global increase in cerebral (18)F-FDG uptake. CONCLUSIONS: Cognitive impairment, reduced cerebral glucose consumption, and alterations in CSF biomarkers were observed in OSA patients, which may reinforce the hypothesis of AD neurodegenerative processes triggered by OSA. Notably, cognition and brain glucose consumption improved after beneficial CPAP treatment. Further studies are needed to evaluate the long-term effects of CPAP treatment on these AD biomarkers. |
format | Online Article Text |
id | pubmed-9468130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94681302022-09-14 (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment Fernandes, Mariana Mari, Luisa Chiaravalloti, Agostino Paoli, Barbara Nuccetelli, Marzia Izzi, Francesca Giambrone, Maria Pia Camedda, Riccardo Bernardini, Sergio Schillaci, Orazio Mercuri, Nicola Biagio Placidi, Fabio Liguori, Claudio J Neurol Original Communication INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This study aimed to measure cognitive performance, CSF biomarkers, and cerebral glucose consumption in OSA patients and to evaluate the effects of continuous positive airway pressure (CPAP) treatment on these biomarkers over a 12-month period. METHODS: Thirty-four OSA patients and 34 controls underwent (18)F-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG PET), cognitive evaluation, and CSF analysis. A subgroup of 12 OSA patients treated with beneficial CPAP and performing the 12-month follow-up was included in the longitudinal analysis, and cognitive evaluation and (18)F-FDG PET were repeated. RESULTS: Significantly reduced glucose consumption was observed in the bilateral praecuneus, posterior cingulate cortex, and frontal areas in OSA patients than controls. At baseline, OSA patients also showed lower β-amyloid(42) and higher phosphorylated-tau CSF levels than controls. Increased total tau and phosphorylated tau levels correlated with a reduction in brain glucose consumption in a cluster of different brain areas. In the longitudinal analysis, OSA patients showed an improvement in cognition and a global increase in cerebral (18)F-FDG uptake. CONCLUSIONS: Cognitive impairment, reduced cerebral glucose consumption, and alterations in CSF biomarkers were observed in OSA patients, which may reinforce the hypothesis of AD neurodegenerative processes triggered by OSA. Notably, cognition and brain glucose consumption improved after beneficial CPAP treatment. Further studies are needed to evaluate the long-term effects of CPAP treatment on these AD biomarkers. Springer Berlin Heidelberg 2022-05-24 2022 /pmc/articles/PMC9468130/ /pubmed/35608659 http://dx.doi.org/10.1007/s00415-022-11182-z Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Fernandes, Mariana Mari, Luisa Chiaravalloti, Agostino Paoli, Barbara Nuccetelli, Marzia Izzi, Francesca Giambrone, Maria Pia Camedda, Riccardo Bernardini, Sergio Schillaci, Orazio Mercuri, Nicola Biagio Placidi, Fabio Liguori, Claudio (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title | (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title_full | (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title_fullStr | (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title_full_unstemmed | (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title_short | (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
title_sort | (18)f-fdg pet, cognitive functioning, and csf biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468130/ https://www.ncbi.nlm.nih.gov/pubmed/35608659 http://dx.doi.org/10.1007/s00415-022-11182-z |
work_keys_str_mv | AT fernandesmariana 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT mariluisa 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT chiaravallotiagostino 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT paolibarbara 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT nuccetellimarzia 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT izzifrancesca 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT giambronemariapia 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT cameddariccardo 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT bernardinisergio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT schillaciorazio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT mercurinicolabiagio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT placidifabio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment AT liguoriclaudio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment |